Kenvue (NYSE:KVUE) PT Raised to $24.00

Kenvue (NYSE:KVUE) had its price objective boosted by research analysts at JPMorgan Chase & Co. from $22.00 to $24.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 14.29% from the stock’s current price.

KVUE has been the topic of a number of other reports. Citigroup reduced their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft reduced their price objective on Kenvue from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. HSBC boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. UBS Group increased their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Trading Down 1.2 %

Shares of NYSE KVUE traded down $0.25 during mid-day trading on Wednesday, reaching $21.00. 1,152,667 shares of the company’s stock were exchanged, compared to its average volume of 19,177,635. The company’s 50-day moving average is $18.53 and its 200-day moving average is $19.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The firm has a market capitalization of $40.21 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 2.07 and a beta of 1.38. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.10.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter last year, the firm earned $0.32 EPS. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Analysts expect that Kenvue will post 1.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KVUE. Beaumont Financial Advisors LLC increased its holdings in shares of Kenvue by 3.0% in the fourth quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock valued at $377,000 after purchasing an additional 509 shares during the period. Manchester Capital Management LLC increased its stake in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares during the period. Poehling Capital Management INC. increased its stake in Kenvue by 0.5% in the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after buying an additional 547 shares during the period. Tradition Wealth Management LLC raised its position in Kenvue by 2.8% during the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after buying an additional 575 shares during the last quarter. Finally, MV Capital Management Inc. lifted its stake in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.